M11.18 Familial chondrocalcinosis, vertebrae

Name of the Condition

• Familial chondrocalcinosis, vertebrae

Summary

Familial chondrocalcinosis, vertebrae is a hereditary condition characterized by the deposition of calcium pyrophosphate dihydrate (CPPD) crystals in the vertebral joints and surrounding tissues. This leads to inflammation, pain, and potential structural changes in the spine. It is a subtype of calcium pyrophosphate deposition disease (CPPD) with a genetic basis, often presenting with localized spinal symptoms. Diagnosis relies on clinical evaluation, imaging, and sometimes crystal identification in joint fluid or tissue.

Causes

Familial chondrocalcinosis, vertebrae is caused by genetic mutations that predispose individuals to abnormal calcium pyrophosphate crystal formation in vertebral cartilage, synovium, or periarticular structures. These mutations may affect enzymes or proteins involved in crystal metabolism, leading to abnormal deposition. The condition is inherited, though the exact genetic pathways vary. Crystal deposition triggers an inflammatory response, contributing to spinal joint damage over time.

Risk Factors

• Genetic predisposition (family history of CPPD or chondrocalcinosis).
• Advanced age (increased risk with aging, though familial cases may present earlier).
• Metabolic conditions affecting calcium or pyrophosphate levels (e.g., hemochromatosis, hyperparathyroidism).
• Spinal trauma or surgery.
• Chronic inflammatory spinal conditions.

Symptoms

• Localized back pain, stiffness, or discomfort.
• Reduced spinal mobility or range of motion.
• Recurrent episodes of acute spinal inflammation.
• Potential radiographic changes (e.g., calcifications) in vertebral joints.

Diagnosis

Diagnosis involves a combination of clinical assessment, patient history (including family history), and imaging studies (e.g., X-rays, CT, or MRI) to detect crystal deposition or structural changes in the vertebrae. Joint fluid aspiration may be performed to identify CPPD crystals under polarized light microscopy, though this is less common in spinal sites. Laboratory tests may rule out other metabolic or inflammatory conditions.

Treatment Options

Treatment focuses on managing symptoms and reducing inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine may alleviate acute pain. Intra-articular corticosteroid injections can provide targeted relief for severe inflammation. Physical therapy helps maintain spinal function and mobility. Long-term management may include monitoring for degenerative changes and addressing associated metabolic factors.

Prognosis and Follow-Up

Prognosis varies based on the extent of crystal deposition and spinal involvement. Early diagnosis and treatment can mitigate pain and preserve function, but chronic deposition may lead to progressive joint damage. Regular follow-up with imaging and clinical evaluations is recommended to monitor spinal health and adjust management as needed.

Complications

• Chronic spinal pain or stiffness.
• Progressive degenerative changes in vertebral joints.
• Reduced quality of life due to mobility limitations.
• Potential nerve compression or spinal instability in advanced cases.

Lifestyle & Prevention

• Maintain a healthy weight to reduce spinal stress.
• Engage in low-impact exercises (e.g., swimming, walking) to support spinal flexibility.
• Avoid activities that strain the spine (e.g., heavy lifting).
• Manage metabolic conditions (e.g., calcium or phosphate imbalances) under medical guidance.
• Follow prescribed treatment plans to minimize inflammation.

When to Seek Professional Help

Seek medical attention if you experience persistent or worsening back pain, sudden loss of spinal mobility, or signs of nerve compression (e.g., numbness, weakness). Acute inflammatory episodes requiring rapid symptom relief also warrant prompt evaluation.

Tips for Medical Coders

Document the specific vertebral involvement and any associated clinical details (e.g., imaging findings, crystal identification) to support code assignment. Ensure the diagnosis aligns with the hereditary nature of the condition and excludes non-familial causes of spinal crystal deposition.